Oxlumo
E446847
Oxlumo is an RNA interference (RNAi) therapeutic used to treat primary hyperoxaluria type 1 by reducing hepatic oxalate production.
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
RNA interference therapeutic
ⓘ
drug ⓘ prescription medicine ⓘ small interfering RNA ⓘ |
| affectsOrgan | liver ⓘ |
| approvedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| belongsToPathway | RNA interference pathway NERFINISHED ⓘ |
| developedBy | Alnylam Pharmaceuticals NERFINISHED ⓘ |
| hasApprovalType | orphan drug ⓘ |
| hasATCCode | A16AX19 ⓘ |
| hasCommonAdverseEffect |
abdominal pain
ⓘ
headache ⓘ injection site reactions ⓘ nasopharyngitis ⓘ |
| hasDosageForm | solution for injection ⓘ |
| hasDosingFrequency |
every three months for maintenance (weight-dependent)
ⓘ
monthly ⓘ |
| hasDrugClass |
RNAi therapeutic
ⓘ
siRNA targeting glycolate oxidase ⓘ |
| hasGenericName | lumasiran NERFINISHED ⓘ |
| hasInternationalNonproprietaryName | lumasiran NERFINISHED ⓘ |
| hasMolecularTarget | HAO1 gene product pathway ⓘ |
| hasRegulatoryStatus | prescription only ⓘ |
| hasTherapeuticArea |
metabolic disorders
ⓘ
nephrology ⓘ |
| indicatedFor |
PH1
ⓘ
primary hyperoxaluria type 1 ⓘ |
| inhibitsExpressionOf | glycolate oxidase ⓘ |
| isAdministeredTo |
adult patients
ⓘ
pediatric patients ⓘ |
| isContraindicatedIn | patients with known hypersensitivity to lumasiran or excipients ⓘ |
| isFirstInClass | RNAi therapeutic for primary hyperoxaluria type 1 ⓘ |
| isUsedAs | chronic therapy ⓘ |
| marketingAuthorizationHolder | Alnylam Pharmaceuticals NERFINISHED ⓘ |
| mechanismOfAction | RNA interference–mediated degradation of HAO1 mRNA ⓘ |
| reduces |
glycolate oxidase activity
ⓘ
hepatic oxalate production ⓘ plasma oxalate levels ⓘ urinary oxalate levels ⓘ |
| resultsIn |
decreased oxalate biosynthesis
ⓘ
increased glycolate levels ⓘ |
| routeOfAdministration | subcutaneous injection ⓘ |
| targets |
HAO1 mRNA
ⓘ
hydroxyacid oxidase 1 mRNA ⓘ |
| treats |
hyperoxaluria-related systemic oxalosis
ⓘ
recurrent kidney stones due to PH1 ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.